Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Anti-rotavirus vaccinations].

J Schmitz1

  • 1Service de gastroentérologie et de nutrition pédiatriques, hôpital Necker-Enfants-malades, Paris, France.

Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie
|October 16, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>Mycobacterium avium</i> complex (MAC) elimination slopes from sputum are potential treatment response biomarkers in patients with HIV and pulmonary MAC.

IJTLD open·2026
Same author

GMP- compliant formulation and quality control of sodium [<sup>124</sup>I]iodide for oral applications.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2025
Same author

Search for B^{0}→K^{*0}τ^{+}τ^{-} Decays at the Belle II Experiment.

Physical review letters·2025
Same author

Search for a Dark Higgs Boson Produced in Association with Inelastic Dark Matter at the Belle II Experiment.

Physical review letters·2025
Same author

Search for P_{cc[over ¯]s}(4459)^{0} and P_{cc[over ¯]s}(4338)^{0} in ϒ(1S,2S) Inclusive Decays at Belle.

Physical review letters·2025
Same author

Distinct HLA Haplotypes Are Associated With an Altered Strength of SARS-CoV-2-Specific T-Cell Responses and Unfavorable Disease Courses.

European journal of immunology·2025

Rotavirus vaccines significantly reduce severe diarrhea in children. The live tetravalent human-rhesus reassortant vaccine (RRT-TV) offers protection, but cost limits its availability in developing nations.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Vaccinology

Context:

  • Rotavirus is a leading cause of severe acute diarrhea in children, contributing to significant mortality and morbidity globally.
  • Vaccine development has evolved from bovine and simian strains to more complex reassortant strains.
  • Previous studies demonstrated vaccine efficacy in diverse geographical and environmental settings.

Purpose:

  • To evaluate the protective efficacy of the live tetravalent human-rhesus reassortant rotavirus vaccine (RRT-TV).
  • To assess the vaccine's impact on reducing the incidence and severity of rotavirus gastroenteritis.
  • To analyze the vaccine's performance across different international environments.

Summary:

  • Prospective, double-blind studies confirmed RRT-TV's protective effect against rotavirus diarrhea.

Related Experiment Videos

  • The vaccine reduces the risk of acute rotavirus diarrhea by 50% and severe dehydrating diarrhea by 70-100%.
  • RRT-TV demonstrated consistent efficacy in the United States, Finland, and Venezuela.

    • Impact:

    • The RRT-TV vaccine has been available in the United States since 1998, offering a crucial tool for pediatric public health.
    • Current high costs restrict the vaccine's accessibility, primarily to developed countries.
    • A significant challenge remains in making this life-saving rotavirus vaccine accessible to developing countries.